Liebel-Flarsheim Angiomat Illumena MRI Contrast Injector

Public supplier signals are visible here. Send an inquiry when the listing looks commercially fit.
Product Details
The Angiomat Illumena represents a significant step forward in Liebel-Flarsheim's esteemed line of contrast delivery systems, building upon the reliability of its predecessors with features tailored for the modern MRI suite. It is specifically engineered to operate safely and effectively within the magnetic resonance imaging environment.
Designed for precision and ease of use, this dual-head injector system facilitates the controlled administration of contrast media and saline. This capability is crucial for a wide range of advanced MR imaging procedures, including perfusion and angiographic studies, where timing and flow rate directly impact diagnostic image quality.
- MRI Compatibility: Engineered for safe operation in the MR environment.
- Dual Syringe Design: Allows for both contrast and saline flush protocols, optimizing image enhancement and patient safety.
- User-Focused Interface: Designed to streamline workflow for technologists, enabling quick setup and protocol management.
- Precise Delivery: Provides accurate control over injection rates and volumes, essential for consistent and repeatable imaging results.
For procurement managers and clinical engineering teams, the Angiomat Illumena is recognized as a workhorse system. Its established presence in imaging centers makes it a practical choice for facilities seeking a reliable and familiar solution for their MRI contrast injection needs.
More from Pramor Medical GmbH









More in Injector MRI



Related editorial coverage
Ultrasound Transducer Common Failure Modes: How to Diagnose, Repair, or Replace
Ultrasound probe image problems? Diagnose lens delamination, oil leaks, cable damage & element dropout. Repair vs replace framework + find repair services on MedTrade.
AI Medical Imaging 2026: What the Clinical Data Actually Says
A data-driven look at AI radiology in 2026: the largest RCT ever conducted, why models crash across populations, and the ROI gap no one talks about.